Dupilumab Discontinuation: Key Risk Factors for Recurrence
Summary of Dupilumab Recurrence Study in Atopic Dermatitis
This study investigated the rate of atopic dermatitis recurrence in patients treated with dupilumab and identified factors associated with increased or decreased risk of relapse.
Key Findings:
Recurrence Rate: 23.4% (95% CI, 16%-30%)
Median Time to Relapse: 29 weeks (range, 22-59)
One patient death occurred during follow-up, linked to serious complications, but no deaths were attributed to atopic dermatitis recurrence itself.
Risk Factors for Recurrence (Statistically Significant):
Comorbid Conjunctivitis: HR 7.912 (P = .026)
Dupilumab Treatment < 16 weeks: HR 5.871 (P =.001)
BMI ≥ 28 kg/m²: HR 5.653 (P < .001)
Male sex: HR 5.634 (P =.004)
Familial Predisposition to Allergy: HR 3.438 (P = .01)
Factors Not Statistically Significant (but showed modest increased risk):
Comorbid Urticaria
Comorbid Allergic Rhinitis
Factors Associated with Lower Risk of Recurrence:
Comorbid Asthma: HR 0.935
Previous Corticosteroid Treatment: HR 0.880
Age > 60: HR 0.763
Disease Duration ≥ 10 years: HR 0.761
Comorbid Chronic Bronchitis: HR 0.416
Study Strengths & consistency with Previous Research:
the study’s findings align with previous research, especially regarding:
Male sex being associated with reduced dupilumab survival and increased atopic dermatitis severity.
High BMI being linked to atopic dermatitis severity.
Allergic rhinitis potentially impacting drug survival.
the investigators emphasize the need for improved management and early intervention strategies for atopic dermatitis relapse.